Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

May 7, 2021

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2031

Conditions
Metastatic Non Small Cell Lung Cancer
Interventions
BIOLOGICAL

LN-145

A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145), followed by IL-2.

BIOLOGICAL

LN-145

A tumor sample is obtained by image-guided core biopsy from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepleting chemotherapy including cyclophosphamide and fludarabine, patient is infused with autologous TIL (LN-145) followed by IL-2.

Trial Locations (64)

1011

RECRUITING

Centre Hospitalier Universitaire Vaudois Lausanne, Lausanne

1066

RECRUITING

Het Nederlands Kanker Instituut Antoni Van Leeuwenhoek Ziekenhuis, Amsterdam

2010

RECRUITING

St. Vincent's Hospital, Darlinghurst

2145

RECRUITING

Westmead Hospital, Westmead

3722

RECRUITING

Severance Hospital, Yonsei University, Seoul

6009

RECRUITING

Hollywood Private Hospital Ramsay, Nedlands

6351

RECRUITING

Samsung Medical Center, Seoul

8091

WITHDRAWN

University Hospital of Zurich/ Universitätsspital Zürich, Zurich

10016

RECRUITING

New York University Langone Medical Center, New York

10029

WITHDRAWN

Icahn School of Medicine at Mount Sinai, New York

10065

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

14263

WITHDRAWN

Roswell Park Cancer Institute, Buffalo

14642

WITHDRAWN

University of Rochester Medical Center, Rochester

15065

RECRUITING

Allegheny General Hospital, Natrona Heights

19111

WITHDRAWN

Fox Chase Cancer Center, Philadelphia

19713

WITHDRAWN

Christiana Care Health System, Newark

21201

RECRUITING

University of Maryland, Baltimore

21565

RECRUITING

Gachon Unversity Gil Medical Center, Incheon

23298

RECRUITING

VCU Medical Center (Virginia Commonwealth University), Richmond

27103

RECRUITING

Novant Health - Winston-Salem, Winston-Salem

27157

RECRUITING

Atrium Health Wake Forest University Health Sciences, Winston-Salem

27514

RECRUITING

University of North Carolina, Chapel Hill

28204

WITHDRAWN

Novant Health - Charlotte, Charlotte

30912

RECRUITING

Augusta University, Augusta

32610

WITHDRAWN

University of Florida Health Cancer Center, Gainesville

32804

WITHDRAWN

AdventHealth Cancer Institute, Orlando

33136

RECRUITING

Sylvester Comprehensive Cancer Center, Miami

33612

RECRUITING

H Lee Moffitt Cancer Center and Research Institute, Tampa

37920

RECRUITING

University of Tennessee Medical Center, Knoxville

38120

RECRUITING

Baptist Cancer Center, Memphis

40202

RECRUITING

University of Louisville, Louisville

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

45219

RECRUITING

University of Cincinnati Medical Center, Cincinnati

48201

RECRUITING

Karmanos Cancer Institute, Detroit

48202

WITHDRAWN

Henry Ford Health System, Detroit

53127

RECRUITING

Universitätsklinikum Bonn, Bonn

55455

RECRUITING

University of Minnesota, Minneapolis

57102

RECRUITING

Sanford Cancer Center, Sioux Falls

57105

RECRUITING

Avera Medical Group Cancer Institute, Sioux Falls

58102

RECRUITING

Sanford Roger Maris Cancer Center, Fargo

60068

WITHDRAWN

Advocate Aurora Health, Park Ridge

60612

RECRUITING

Rush University Medical Center, Chicago

RECRUITING

University of Illinois Hospital & Health Sciences System, Chicago

68167

RECRUITING

Universitätsklinikum Mannheim, Mannheim

68198

RECRUITING

University of Nebraska Medical Center, Omaha

73104

WITHDRAWN

University of Oklahoma, Oklahoma City

75246

WITHDRAWN

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

77030

RECRUITING

Houston Methodist, Houston

90033

WITHDRAWN

University of Southern California, Los Angeles

91010

WITHDRAWN

City of Hope, Duarte

92037

WITHDRAWN

UC San Diego Moores Cancer Center, La Jolla

97239

RECRUITING

Oregon Health and Science University, Portland

98109

RECRUITING

Seattle Cancer Care Alliance, Seattle

168583

RECRUITING

National Cancer Centre Singapore, Singapore

02215

WITHDRAWN

Dana Farber Cancer Institute, Boston

08103

RECRUITING

MD Anderson Cooper, Camden

M5G 2C1

RECRUITING

Princess Margaret Cancer Centre, Toronto

QC H2X 3E4

RECRUITING

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

01307

RECRUITING

Universitätsklinikum Carl Gustav Carus, MK I, Dresden

SW36JJ

RECRUITING

Royal Marsden Hospital, Chelsea

W1G 6AD

RECRUITING

Sarah Cannon Research Institute, London

WC1E 68T

RECRUITING

University College London, London

M10 4BX

RECRUITING

The Christie NHS Foundation Trust, Manchester

SE1 9RT

RECRUITING

Guy's Hospital, London

Sponsors
All Listed Sponsors
lead

Iovance Biotherapeutics, Inc.

INDUSTRY

NCT04614103 - Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Biotech Hunter | Biotech Hunter